AIDS patient death caused by novel Cryptococcus neoformans × C. gattii Hybrid [PDF]
Interspecies hybrids of Cryptococcus neoformans and C. gattii have only recently been reported. We describe a novel C. neoformans × C. gattii hybrid strain (serotype AB) that was previously described as C.
Ferry Hagen +13 more
core +4 more sources
Cryptococcus gattii serotype-C strains isolated in Bangalore, Karnataka, India
During a retrospective study on cryptococcosis carried out in Bangalore, Karnataka, India, four Cryptococcus gattii strains were isolated from one HIV-positive and three HIV-negative patients, two of which had unknown predisposing conditions.
N. Chandrashekar +5 more
core +4 more sources
Endophytic fungal compounds active against Cryptococcus neoformans and C. gattii [PDF]
Infections with Cryptococcus are invasive mycoses associated with significant morbidity and mortality, mainly in immunosuppressed patients. Several drugs have been introduced to combat these opportunistic infections.
Rosa, Luiz Henrique +27 more
core +3 more sources
Gene, virulence and related regulatory mechanisms in Cryptococcus gattii. [PDF]
Cryptococcus gattii is a kind of basidiomycetous yeast, which grows in human and animal hosts. C. gattii has four distinct genomes, VGI/AFLP4, VGII/AFLP6, VGIII/AFLP5, and VGIV/AFLP7. The virulence of C. gattii is closely associated with genotype and related stress-signaling pathways, but the pathogenic mechanism of C.
Huang Y +8 more
europepmc +2 more sources
Methods for Antifungal Susceptibility Testing of the Cryptococcus neoformans/C. gattii Complex: Strengths and Limitations. [PDF]
When method-dependent categorical endpoints are available, namely either BPs or ECVs, MICs could aid in selecting the best treatment agent(s). BPs can categorize an isolate as either susceptible or resistant while the ECVs/ECOFFs can distinguish the wild type (WT, no known resistance mechanisms) from the Non-WT (NWT, harboring resistant mechanisms ...
Espinel-Ingroff A, Cantón E.
europepmc +5 more sources
Treatment with pCramoll Alone and in Combination with Fluconazole Provides Therapeutic Benefits in C. gattii Infected Mice. [PDF]
Cryptococcus gattii is one of the main causative agents of cryptococcosis in immunocompetent individuals. Treatment of the infection is based on the use of antimycotics, however, the toxicity of these drugs and the increase of drug-resistant strains have driven the search for more effective and less toxic therapies for cryptococcosis.
Jandú JJ +11 more
europepmc +5 more sources
Immunity to Cryptococcus neoformans and C. gattii during cryptococcosis. [PDF]
The vast majority of infection with cryptococcal species occurs with Cryptococcus neoformans in the severely immunocompromised. A significant exception to this is the infections of those with apparently normal immune systems by Cryptococcus gattii. Susceptibility to cryptococcosis can be broadly categorised as a defect in adaptive immune responses ...
Gibson JF, Johnston SA.
europepmc +4 more sources
1691. Cryptococcus Species Other than C. neoformans and C. gattii: Are They Clinically Significant? [PDF]
Abstract Background Cryptococcus sp. is a major cause of opportunistic infections in immunocompromised patients, with nearly all cases due to C. neoformans or C. gattii. There are occasional reports of other Cryptococcus species causing invasive human disease.
Cano Cevallos E, Yetmar Z, Razonable R.
europepmc +2 more sources
NEUROCRIPTOCOCOSE POR C. GATTII EM PACIENTES HIV/AIDS
Introdução: A infecção por Criptococcus gattii geralmente se apresenta como uma doença indolente e mais comumente envolve o sistema nervoso central (SNC) e os pulmões. A infecção neurológica é mais comum, sendo a forma predominante em pacientes infectados pelo HIV. Ao contrário de C.
Adriana Neis Stamm +6 more
openaire +2 more sources
Genotyping of MexicanCryptococcus neoformansandC. gattiiisolates by PCR-fingerprinting [PDF]
Cryptococcosis in México is caused by both species of the Cryptococcus species complex i.e., Cryptococcus neoformans and C. gattii. The current study was aimed to determine genetic variability of 72 Mexican clinical isolates using PCR-fingerprinting with the primer M13.
L R Castañón, Olivares +7 more
openaire +2 more sources

